Table 3.
Cost‑effectiveness estimates in Asia (7 studies)
| References | Country/region | Intervention and comparator | Δ Cost (US$) | Δ Effectiveness (QALY) | ICER (US$) | Cost-effectiveness threshold (US$) | Intervention cost effective? (+/−) |
|---|---|---|---|---|---|---|---|
| Traditional NSAIDs and/or coxibs | |||||||
| Turajane 2012 [62] | Thailand | Celecoxib vs NSAID | $0.84 | 0.019 | $44.4/QALY | NR | + |
| Nasef 2015 [66] | Saudi Arabia | Celecoxib + PPI vs ibuprofen + PPI | $120.32 | 0.06 | $1980.88 | $2255/QALY | + |
| Ibuprofen + PPI vs no treatment | $1460.39 | 0.34 | $4242.90 | $2255/QALY | + | ||
| Karasawa 2021 [74] | Japan | Celecoxib vs loxoprofen | $62.02 | 0.024 | $53,466.92 | NR | + |
| Sun 2021 [76] | China | Imrecoxib vs diclofenac (lower risk of GI and CV events) | $614.22 | 1.49 | $413.90 | $30,921/QALY | + |
| Imrecoxib vs diclofenac (higher risk of GI and CV events) | $571.06 | 1.13 | $507.89 | $30,921/QALY | + | ||
| Chirikov 2021 [73] | United Arab Emirates | Celecoxib vs ibuprofen | $38.77 | 0.0032 | $11,854.92 | $41,227–$123,682/QALY | + |
| Celecoxib vs naproxen | $84.22 | 0.002 | $40,999.56 | $41,227–$123,682/QALY | + | ||
| IA injections | |||||||
| Yen 2004 [44] | Taiwan | Celecoxib vs naproxen | $67.94 | 0.0023 | $29,178.43 | 2002 Taiwan GDP per capita ($18,399) $46,773/QALY | + |
| Yen 2004 [44] | Taiwan | Hyaluronan vs celecoxib | $181.19 | 0.0031 | $58,447.97 | 2002 Taiwan GDP per capita ($18,399) $46,773/QALY | − |
| Chou 2009 [35] | Taiwan | Hylan G-F 20 vs sodium hyaluronate | $51.27 | 0.019 | Dominant | NR | + |
CV cardiovascular disease, GI gastrointestinal, IA intra-articular, ICER incremental cost-effectiveness ratio, NR not reported, NSAID non-steroidal anti-inflammatory drug, PPI proton pump inhibitor, QALY quality-adjusted life-year